Spyre Therapeutics (SYRE) Net Cash Flow (2015 - 2026)

Spyre Therapeutics' Net Cash Flow history runs 12 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• Quarterly Net Cash Flow rose 128.01% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.7 million (up 127.14% YoY) and the FY2025 annual result came in at -$3.7 million, up 96.29% from the prior year.
• Net Cash Flow was $11.5 million for Q1 2026 at Spyre Therapeutics, down from $20.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $200.1 million in Q2 2023 and bottomed at -$182.4 million in Q2 2024.
• A 5-year average of $4.7 million and a median of $11.5 million in 2026 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 11226.75% — and 2024, when it jumped 30582.54%.
• Spyre Therapeutics' Net Cash Flow stood at -$4.1 million in 2022, then jumped by 2445.66% to $97.3 million in 2023, then sank by 81.65% to $17.9 million in 2024, then advanced by 16.61% to $20.8 million in 2025, then sank by 44.95% to $11.5 million in 2026.
• Business Quant data shows SYRE's Net Cash Flow at $11.5 million in Q1 2026, $20.8 million in Q4 2025, and -$16.8 million in Q3 2025.